CD160 and neoplasm: The development of biologics targeting HVEM/BTLA/CD160/LIGHT is still in its infancy and will require a deeper understanding on how this pathway works during the process of T cell activation and differentiation and in the interplay tumor, tumor microenvironment, and the anti-tumor immune response.